EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic evaluation of intralesional tranexamic acid in higher concentration for treatment of facial melasma

Jyoti, Saurabh Sharma, Guneet Awal, Roopam Bassi, Jasleen Kaur

Journal of Pakistan Association of Dermatologists · 02.07.2024 · 34 (3) · 671-677

DOI: 10.66344/jpad.v34i3.2838 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pakistan Association of Dermatologists, online erschienen am 02.07.2024. Verfasst von Jyoti und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Melasma is a chronic relapsing hyperpigmentary disorder. As the entire etiopathogenesis of melasma is not well understood, there are chances of development of new therapeutic modalities. Tranexamic acid (TXA) has been used in a variety of formulations; nevertheless, there are few research, data and opinions regarding the optimal dosage of intralesional TXA in melasma.

Methods

Total 32 patients were enrolled in our study from January 2023 to June 2023. Injection TXA (0.05 ml) was given intralesionally 1cm apart on entire facial melasma lesion and repeated after every 4 weeks till lesions cleared or a maximum of 6 sessions. Follow up was done at every visit and after 3 months of last session for relapse. Clinical improvement was measured by percentage reduction in mMASI at baseline, at every session and at follow up.

Results

More than 50% patients showed good to very good response with significant reduction in mMASI from 8th week onwards as compared to baseline. Most of the patients were satisfied with their recovery following therapy and reported no significant adverse effects.

Conclusion

TXA was found to be efficacious in all types of melasma. Better response was seen in epidermal and mixed types in comparison to dermal melasma. We recommend a dosage of 50mg/ml at monthly intervals as optimal dosage for an effective therapy in all types of melasma.

Zitieren

APA

Jyoti, Sharma, S., Awal, G., Bassi, R., & Kaur, J. (2024). Therapeutic evaluation of intralesional tranexamic acid in higher concentration for treatment of facial melasma. Journal of Pakistan Association of Dermatologists, 34(3), 671-677. https://doi.org/10.66344/jpad.v34i3.2838

Vancouver

Jyoti, Sharma S, Awal G, Bassi R, Kaur J. Therapeutic evaluation of intralesional tranexamic acid in higher concentration for treatment of facial melasma. Journal of Pakistan Association of Dermatologists. 2024;34(3):671-677. doi:10.66344/jpad.v34i3.2838

BibTeX
@article{Jyoti2024,
  author = {Jyoti and Sharma, Saurabh and Awal, Guneet and Bassi, Roopam and Kaur, Jasleen},
  title = {Therapeutic evaluation of intralesional tranexamic acid in higher concentration for treatment of facial melasma},
  journal = {Journal of Pakistan Association of Dermatologists},
  year = {2024},
  volume = {34},
  number = {3},
  pages = {671--677},
  doi = {10.66344/jpad.v34i3.2838}
}
Kostenlos starten →